Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma

mouse model, where we demonstrate increased TAN survival with a rise in Bcl-xL similarly to LUAD. However, unlike in LUAD, inhibiting Bcl-xL alone was insufficient to alter tumor progression in LUSC. After carboplatin and paclitaxel treatment, a combination chemotherapy used in human LUSC, we detected increased neutrophils in circulation, spleen and tumors, and increased Bcl-xL in neutrophils and TANs. Bcl-xL blockade decreased the pool of Bcl-xL-high TANs and synergized with chemotherapy. Altogether, our results suggest distinct outcomes for targeting TANs in different tumor types and reinforce the concept of repurposing BH3 mimetics against cancer.

Authors

Institutions

Publication Details

Journal
EMBO Molecular Medicine
Published
2026-03-31
DOI
https://doi.org/10.1038/s44321-026-00401-z
Primary Topic
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma

Thierry Berghmans, Fabienne Andris, Etienne Meylan, Abbie S. Ireland et al.
EMBO Molecular Medicine
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
article

Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma

Thierry Berghmans, Fabienne Andris, Etienne Meylan, Abbie S. Ireland, Sarika Rana, Beatrice Parma, Sébastien Denanglaire, Déborah Lécuyer, Stanislas Goriely, Trudy G. Oliver, Anita Bodac, Jean Yannis Perentes, Pieter Demetter, Abdullah Mayet, Amaury Defruit, Mariana Brandão
article en

Abstract

mouse model, where we demonstrate increased TAN survival with a rise in Bcl-xL similarly to LUAD. However, unlike in LUAD, inhibiting Bcl-xL alone was insufficient to alter tumor progression in LUSC. After carboplatin and paclitaxel treatment, a combination chemotherapy used in human LUSC, we detected increased neutrophils in circulation, spleen and tumors, and increased Bcl-xL in neutrophils and TANs. Bcl-xL blockade decreased the pool of Bcl-xL-high TANs and synergized with chemotherapy. Altogether, our results suggest distinct outcomes for targeting TANs in different tumor types and reinforce the concept of repurposing BH3 mimetics against cancer.

EMBO Molecular Medicine
Université Libre de Bruxelles (BE), Duke University (US), Institut Jules Bordet (BE), Centre Hospitalier Universitaire Vaudois (CH), Institute of Pathology and Genetics (BE), Swiss Cancer Center Léman (CH), École Polytechnique Fédérale de Lausanne (CH), University of Lausanne (CH)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Fonds De La Recherche Scientifique - FNRS, Fondation Rose et Jean Hoguet
Openalex Percentile: Top 36%
Neutrophil, Myeloperoxidase and Oxidative Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.